Timeline of 10 years of genomic profiling in AML patients accompanied by major breakthroughs in genomically inspired targeted therapies. IDH1 and IDH2 are the only genes to have major drug development advancements in the era since the first AML genome was sequenced. Blue lines represent drug development milestones, and red lines represent genomic advances.